Page 66 - Demo
P. 66
Chapter 364days. At the end of the trial period, the participant will have a second and final clinical visit to evaluate the symptoms and study. In consultation with the treating physician, patients may continue with MPH treatment, whether or not at a different dosage. Three months after terminating the N-of-1 trial, another contact moment will take place for a follow-up measurement in which the questionnaires will be filled out and the goals and items of GAS and PQ will be discussed again. To reduce burden as much as possible, assessments solely occur by phone calls apart from the two study visits. The total duration of the trial will be 14 weeks with the additional follow-up measurement after three months. Enrollment*AllocationBaselineDose titrationWashoutCycle 1Cycle 2Cycle 3*Follow-upTime point (weeks)0 1 2 3-6 7-10 11-14 27Enrolment Eligibility screen XInformed consent XAllocation XInterventions Methylphenidate X X X X XPlacebo X X X XAssessments SDQ (daily) X X X X XEDI (daily) X X X X XGAS X X X X X XPQ X X X X X XSide effects X X X X XFigure 2. Time schedule of enrolment, interventions, and assessments. Underlined crosses (X) indicate assessments via phone calls. Asterisks (*) indicate the moment with a clinical visit. EDI Emotion Dysregulation Inventory, GAS Goal Attainment Scaling, PQ personal questionnaire, SDQ Strengths and Difficulties Questionnaire.Blinding, treatment allocation, randomizationParticipants, parents, caregivers, supervisors of daily activities, clinicians and researchers will all be blinded during the N-of-1 trial. The random allocation sequence will be generated and implemented by the hospital pharmacist for block randomization in a 1:1 ratio and sequentially numbered packages. Participants and the treating physician will be deblinded after Annelieke Muller sHL.indd 64 14-11-2023 09:07